Antibiotic Prophlaxis for High-risk Laboring Women in Low Income Countries

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

756 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-12

Study Completion Date

2020-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study, performed over a course of 3 years in 5 collaborating hospitals in Cameroon, Africa, will randomize 750 women in labor with prolonged rupture of membranes ≥ 8 hours or prolonged labor ≥ 18 hours to identical oral regimens of 1 gram of azithromycin, 1 gram of azithromycin+2 grams of amoxicillin or placebo. Women will be followed to ascertain maternal infectious outcomes and perinatal outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Azithromycin for Preventing Maternal and Neonatal Infections During Labor.

NCT06958146

Maternal and Neonatal Sepsis Intrapartum Antibiotics

NOT_YET_RECRUITING PHASE4

Azithromycin-Prevention in Labor Use Study (A-PLUS)

NCT03871491

Maternal Death Maternal Infections Affecting Fetus or Newborn Neonatal SEPSIS +3 more

COMPLETED PHASE3

Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis & Death

NCT03199547

Neonatal SEPSIS

COMPLETED PHASE3

Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial

NCT06605118

Obstetrical Complications Labor and Delivery Complication Cesarean Delivery

RECRUITING PHASE3

Efficacy of Azithromycin in MSAF Cases to Improve Maternal and Neonatal Outcomes

NCT05118984

Meconium Stained Azithromycin Postpartum Endometritis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This 3-arm study is a large randomized clinical trial designed to evaluate the comparative effectiveness and safety of single dose oral azithromycin or combined azithromycin+amoxicillin compared to placebo for the prevention of peripartum infections and sepsis in laboring women. We have previously shown the effectiveness of azithromycin for extended spectrum antibiotic prophylaxis in addition to the standard cephalosporin alone for reduction of post-cesarean infections. In LICs, the fraction of maternal infection and sepsis from cesarean delivery is minimal. Therefore, it is necessary to evaluate strategies aimed at reducing these morbidities in women who have vaginal births. There is an increased risk of infection in women who have prolonged labor or prolonged rupture of membranes. Drawing from our findings with azithromycin-based extended antibiotic prophylaxis for cesarean delivery, we propose to adapt the intervention and evaluate a single oral dose of azithromycin (with or without oral amoxicillin) to prevent maternal peripartum infection and sepsis. This study, performed over a course of 3 years in 5 collaborating hospitals in Cameroon, Africa, will randomize 750 women in labor with prolonged rupture of membranes ≥ 8 hours or prolonged labor ≥18 hours to 1 gram of oral azithromycin, 1 gram of azithromycin+2 grams of amoxicillin, compared to usual care (placebo). Women will be followed to ascertain maternal infectious outcomes and perinatal outcomes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postpartum Sepsis Postpartum Endometritis Postpartum Fever

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized Controlled Trial

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Azithromycin and amoxicillin placebo

Patients in this arm will receive 1 gram oral azithromycin as a single dose and amoxicillin placebo.

Group Type EXPERIMENTAL

Azithromycin

Intervention Type DRUG

Azithromycin tablet

Placebo

Intervention Type DRUG

Placebo tablet

Azithromycin + amoxicillin

Patients in this arm will receive 1 gram oral azithromycin and 2 grams oral amoxicillin in a single dose.

Group Type EXPERIMENTAL

Azithromycin and amoxicillin

Intervention Type DRUG

azithromycin and amoxicillin

Usual Care

This arm will consist of routine care at the clinical sites (which is usually no antibiotic). They will receive placebo (for azithromycin) and placebo (for amoxicillin)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Azithromycin

Azithromycin tablet

Intervention Type DRUG

Azithromycin and amoxicillin

azithromycin and amoxicillin

Intervention Type DRUG

Placebo

Placebo tablet

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

azithromycin, amoxicillin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women ≥ 37 weeks' viable singleton or twin gestation in labor planning a vaginal delivery with

1. Prolonged membrane rupture (≥8 hours) or
2. Prolonged labor (≥18 hours).

Exclusion Criteria

* Clinical chorioamnionitis or any other active bacterial infection (e.g. pyelonephritis, pneumonia, abscess) at time of randomization: because standard antibiotic therapy for these conditions may confound trial intervention.
* Allergy to azithromycin or amoxicillin
* Plan for cesarean delivery prior to enrollment
* Fetal demise or major congenital anomaly: Major congenital anomalies may confound assessment of neonatal outcomes and every attempt will be made up front to exclude them from randomization. However, some unrecognized fetal anomalies may inevitably be randomized. These will not be excluded post-randomization from the primary (maternal outcome) analysis; they will be taken into consideration in the secondary analyses of neonatal outcomes.

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes